Navigation Links
Peptimmune Announces First Close of Series D Private Financing
Date:1/17/2008

CAMBRIDGE, Mass., Jan. 17 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a first close of $8.2 million of a Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, as well as certain other investors, including its Chairman of the Board. The Company expects a second close in Q2/2008, which may involve an additional new investor. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's PI-2301 for the treatment of multiple sclerosis.

"We are pleased with the level of continuing support from our existing investors and the opportunity to expand our syndicate," stated Thomas P. Mathers, President and CEO. "The Series D investment will provide the necessary capital to complete two clinical trials by the end of 2008: the current single ascending dose in healthy volunteers and a multiple ascending dose in multiple sclerosis patients, expected to start in Q2/08. The completion of these two studies will offer proof of principal for PI-2301, which is a second generation copolymer targeted at treating patients with relapsing and remitting multiple sclerosis."

Financing Two Clinical Trials in Multiple Sclerosis

Peptimmune is currently completing its Phase I single ascending dose study for PI-2301, a double blind placebo controlled randomized study that involves 56 healthy male volunteers who will receive the drug in eight escalating dose cohorts. Following establishment of safety at potentially therapeutic doses, the Company will initiate its first repeat dose study in multiple sclerosis patients in Q2/2008, where it will explore safety, pharmacokinetics and pharmacodynamics over eight to twelve weeks of dosing.

About PI-2301

PI-2301 is a second generation peptide copolymer from a similar compound class as
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Vasogen Announces 2007 Year-End Results
4. RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
5. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
6. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
7. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
8. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
9. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
10. Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend
11. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/w48l6t/global_cancer ... "Global Cancer Biosimilars Market Opportunity Outlook" report ... cancer biosimilar is required because they have both ... dominated the cancer segment for several decade but ... few years. They are biologic in origin and ...
(Date:6/26/2015)... DALLAS , June 26, 2015 ... Animal Fat), Application (Hydraulic Fluids, Metalworking fluids, Chainsaw oils, ... Automobile) & by Region - Global trends and Forecasts ... expected to reach $2,972.13 Million by 2020 at a ... Browse 160 market data Tables and   66 ...
(Date:6/25/2015)... 2015 Last June, a dedicated global team of ... using large-scale genome sequencing. Their research, which was written on ... journal Cell (Park 2015) , reveals critical ... months of the recent Ebola outbreak. Today Authorea ... workflows, and full edit history of the paper are ...
(Date:6/25/2015)... , June 25, 2015 Current asthma ... immune cells or by dilating the airways, can ... Children,s Hospital, Brigham and Women,s Hospital and Harvard ... controlling asthma: targeting certain sensory nerve endings in ... Reporting online in the journal Neuron ...
Breaking Biology Technology:Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Biolubricants Market Worth $2,972.13 Million by 2020 2Biolubricants Market Worth $2,972.13 Million by 2020 3Open Science Takes Major Leap Forward 2Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5
... 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ... 2007 after the market closes on Tuesday, November 6,2007. ... p.m. EST,1:30 p.m. PST, on the company,s website. ... the Company,s website at, http://www.cvt.com and go to ...
... - The Board of,Directors of Immunotec Inc. is ... A. Northrop as President and Chief Executive Officer, ... Board of Directors of Immunotec Inc., Mr. Northrop ... success in rapid growth,situations, Mr. Northrop has impressive ...
... an Eden Prairie-,based molecular diagnostics service and technology company, ... its CFO, and Elizabeth A. Skinner,as VP - Legal, ... of Edwin Watts Golf, and has previously,served as VP ... Allied Signal,Aerospace, and corporate controller of NCR Corporation. He ...
Cached Biology Technology:CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Immunotec Inc. announces appointment of President & CEO James A. Northrop 2Access Genetics Announces New Executive Appointments 2
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
(Date:6/15/2015)... YORK , June 15, 2015 ... today from Telstra reveals the majority of US consumers using ... them via biometrics, such as fingerprint and voiceprint, instead of ... According to Telstra,s " Mobile Identity   - ... " report, with smartphones now the primary channel used ...
(Date:6/11/2015)... 11, 2015 Daon, a global leader ... its IdentityX Mobile Authentication Platform v4.0 has been ... is an industry consortium launched in 2013 to ... stronger authentication.  In order to receive certification, a ... series of tests that measure compliance and ensure ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Group, Inc. (OTC Bulletin Board: MDXG ), ... biomaterial-based products, announced today that its results for the ... and Company guidance will be released after the closing ... timing of the earnings announcement allows MiMedx time to ...
... the oocysts from the Cryptosporidium genus and cysts ... greatest public health problems in water supply, because these parasites ... Hermida, a scientist at the Galician Institute for Food Quality ... A team led by this researcher took 232 water samples ...
... at IRB Barcelona have completed the 3D structural sequence ... substances between the extra and intracellular milieu. This finding ... occur in these relevant proteins during basic cell processes, ... cell volume, and nerve transmission. The exchange ...
Cached Biology News:MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results 2Parasitic protozoons survive waste water and drinking water treatment plants in Galicia 2Researchers achieve a full film frame of a family of proteins essential for cell function 2
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... for relax positively and negatively supercoiled DNA in ... , Studying the effects of supercoiling on transcription ... vitro , Determining the degree of supercoiling ... plasmids that differ in length by only one ...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: